Duncan Williams Upgrades Salix Pharmaceuticals (SLXP) to Buy; Expecting Xifaxan IBS Trial
Tweet Send to a Friend
Duncan Williams upgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Hold to Buy. PT $47.
Duncan analyst says, "We previously believed that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Duncan analyst says, "We previously believed that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
